ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$252.93
arrow_downward
-1.18%(-3.03) 1D
Sep 28, 12:26:08 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$256.28
High
$256.60
Low
$248.12
Mkt. cap
33.84B
Avg. vol.
1.60M
Volume
416.82K
P/E ratio
43.05
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.31
Shares outstanding
133.81M
No. of employees
2K
Open
$256.28
High
$256.60
Low
$248.12
Mkt. cap
33.84B
Avg. vol.
1.60M
Volume
416.82K
P/E ratio
43.05
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.31
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Pluang
·
6 minutes ago
Alnylam shares drop 18% after AstraZeneca/Ionis trial failure, but outlook remains cautiously optimistic.
Seeking Alpha
·
30 minutes ago
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY)
Zacks
·
1 hour ago
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Yahoo Finance
·
2 hours ago
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.